Caption Management’s Iovance Biotherapeutics IOVA Stock Holding History

Caption Management’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-85,000	Closed	-$629K	–	1787
2024 Q4	$629K	Buy	+85,000	New	+$788K	0.01%	1032
2024 Q3	–	Sell	-35,000	Closed	-$281K	–	1445
2024 Q2	$281K	Sell	35,000 -95,000	-73%	-$1.02M	﹤0.01%	910
2024 Q1	$1.93M	Sell	130,000 -145,000	-53%	-$1.69M	0.03%	539
2023 Q4	$2.24M	Buy	275,000 +177,500	+182%	+$929K	0.03%	585
2023 Q3	$444K	Buy	97,500 +67,500	+225%	+$441K	0.01%	960
2023 Q2	$211K	Hold	30,000	–	–	﹤0.01%	933
2023 Q1	$183K	Buy	+30,000	New	+$207K	﹤0.01%	928
2021 Q4	–	Sell	-120,000	Closed	-$2.96M	–	1756
2021 Q3	$2.96M	Buy	+120,000	New	+$2.83M	0.03%	622
2019 Q4	–	Sell	-30,000	Closed	-$546K	–	926
2019 Q3	$546K	Buy	+30,000	New	+$663K	0.03%	476

Other funds holding IOVA

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MFM

MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

HRCM

Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Caption Management's IOVA Position: Q1 2025 in Review

Caption Management sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 38,500 shares — an estimated $285K sold.

Caption Management first reported a position in IOVA in Q2 2019 and held it in 15 quarters. The position peaked at $4.35M in Q1 2020. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

Caption Management reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
Caption Management sold 38,500 Iovance Biotherapeutics shares in Q1 2025, an estimated $285K.
Caption Management first reported a position in Iovance Biotherapeutics in Q2 2019 and held it in 15 quarters.
Caption Management's Iovance Biotherapeutics position peaked at $4.35M in Q1 2020.
301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Caption Management's 13F filing for Q1 2025, filed 15 May 2025.